Floatz logo

68 assets in Lung Carcinoma

Therapeutic assets addressing Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Hafnium Oxide
Lung Carcinoma
M.D. Anderson Cancer CenterP1CC (43)
Infliximab
Lung Carcinoma
M.D. Anderson Cancer CenterP1CC (43)
Prednisone
Lung Carcinoma
M.D. Anderson Cancer CenterP1CC (43)
Vedolizumab
Lung Carcinoma
M.D. Anderson Cancer CenterP1CC (43)
Veliparib
Lung Carcinoma
National Cancer Institute (NCI)P1CC (43)
Bbo-10203
Lung Carcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)P1CC (41)
Bbo-11818
Lung Carcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)P1CC (41)
Bbo-8520
Lung Carcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)P1CC (41)
Brigatinib
Lung Carcinoma
University of California, San FranciscoP1CC (41)
Cetuximab
Lung Carcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)P1CC (41)
lyl797
Lung Carcinoma
Lyell Immunopharma, Inc.P1CC (41)
18f-αvβ6-bp
Lung Carcinoma
Julie L. Sutcliffe, Ph.DEarly P1C (39)
89zr-dfo-n-suc-c9scfv
Lung Carcinoma
Var2 PharmaceuticalsEarly P1C (39)
89Zr-DFO-N-Suc-F8scFv
Lung Carcinoma
Var2 PharmaceuticalsEarly P1C (39)
68ga-nota-nectin-4 antibody fragment
Lung Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyN/AD (30)
Danvatirsen
Lung Carcinoma
M.D. Anderson Cancer CenterP2NR ()
Showing 51 to 68 of 68 assets
PreviousPage 2 of 2Next